Glooko Stock
Unified platform for Diabetes management
Sign up today and learn more about Glooko Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Glooko Stock
Glooko is the universal diabetes platform that provides insights to improve outcomes for people with diabetes (PWDs) and their care teams. Glooko connects to the world’s most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient information such as glucose level, food, insulin, medications, blood pressure, diet and weight data. Trusted by the world’s leaders in diabetes care, we are in over 7,000 clinical locations and used by over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com.
Investors
Canaan Partners
Instacart, Snyk, Dragos, Turo, The RealReal, MindTickle, Lending Club, Berkshire Grey, Tomorrow.io, Apartment List
Social Capital
Relativity Space, Slack, Netskope, Box, BetterUp, Greenlight, Guild Education, Flutterwave, Palmetto Clean Technology, Groq
Medtronic
Funding History
| November 2010 | $1.0M |
|---|---|
| January 2012 | $3.5M |
| January 2014 | $7.0M |
| March 2015 | $16.5M |
| September 2016 | $8.0M |
| June 2017 | $35.0M |
Management
Chief Executive Officer
Russ Johannesson
Co-Founder
Yogen Dalal
Chief Medical Officer
Michael S. Greenfield
Chief Commercial Officer
David Conn
Press
vator - Jan, 13 2024
Better Therapeutics CEO talks partnership with Glookothefly - Jan, 5 2024
Better Therapeutics and Glooko team to to integrate AspyreRx to treat T2Dfiercebiotech - Jan, 4 2024
Better Therapeutics adds digital treatment into Glooko’s diabetes management platformprnewswire - Oct, 25 2023
Glooko Appoints Enrique Conterno, former Eli Lilly & Company Senior Executive, to Board of Directorsprnewswire - May, 9 2023
Glooko Unveils Redesigned Mobile AppEquityZen Recognized As:
